Ceftolozane-Tazobactam

Restricted
Restricted

C. diff Risk

High

Oral Bioavailability

NA

Approximate Cost

$$$$

Dosing

1.5 - 3 g IV Q8H

No dose adjustment

Data is insufficient in the Pediatric population

Infectious Diseases consult required for use.

Should be reserved for patients with little or no other treatment alternatives.

Reserved primarily for management of documented infections caused by CRE

General Information

Common Usage

In patients with documented multi-drug resistant (MDR) pseudomonas or CRE organisms

Drug Monitoring

Laboratory

  • CBC, CMP weekly

Adverse Effects

  •  GI intolerance

  •  Headache

Pharmacology

Antimicrobial class: Cephalosporin Combination

Pregnancy category: B